fda drug shortages semaglutide injection status resolved 2025 Ozempic and Wegovy officially moved off FDA's shortage list Novo's Wegovy and Ozempic removed

Use of ibutamoren may cause serious side effects including increased appetite, water retention, fatigue, muscle pain, potential alterations in glucose metabolism and insulin sensitivity, and even may increase the potential for congestive heart failure in certain individuals

Ekinci EI, Jerums G, Skene A, Crammer P, Power D, Cheong KY, et al

Dulaglutide is a long-acting GLP-1RA used for T2DM with demonstrated cardiovascular benefits.[10] Liraglutide, another long-acting GLP-1RA, is used for T2DM and obesity management and is under investigation for Alzheimers disease and metabolic-associated hepatic steatosis.[4] Lixisenatide, a short-acting GLP-1RA, shows comparable efficacy to exenatide and liraglutide for T2DM management, and is now combined with insulin glargine.[23] Semaglutide, available in injectable and oral forms, has demonstrated benefits in promoting weight loss, reducing risk of cardiovascular events, and slowing progression of diabetic CKD.[24] Finally, tirzepatide is a dual agonist for receptors of GLP and glucose-dependent insulinotropic polypeptide (GIP), a hormone released from the intestines in response to macronutrients.[25] These two mechanisms of action have synergistic glucose-lowering and weight loss effects with lower side effect rates than other GLP-1RAs.[25] Tirzepatide has also been shown to result in blood pressure reduction, obstructive sleep apnea control, and improved cholesterol in T2DM patients.[5] Table

"If it's that great and it's helping the whole population of obesity great, but tell people what can happen to them

This article explores how GLP1 therapies work, why their clinical potential extends across multiple conditions, and what has driven their unprecedented uptake

Our approach is built on trust, transparency, and a deep understanding of what it takes to achieve sustainable health transformations